Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are currently under clinical development for treating anemia in chronic kidney disease (CKD), but it is important to monitor their cardiovascular safety. Genetic variants can be used as predictors to help inform the potential risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Harlow, Charli E., Gandawijaya, Josan, Bamford, Rosemary A., Martin, Emily-Rose, Wood, Andrew R., van der Most, Peter J., Tanaka, Toshiko, Leonard, Hampton L., Etheridge, Amy S., Innocenti, Federico, Beaumont, Robin N., Tyrrell, Jessica, Nalls, Mike A., Simonsick, Eleanor M., Garimella, Pranav S., Shiroma, Eric J., Verweij, Niek, van der Meer, Peter, Gansevoort, Ron T., Snieder, Harold, Gallins, Paul J., Jima, Dereje D., Wright, Fred, Zhou, Yi-hui, Ferrucci, Luigi, Bandinelli, Stefania, Hernandez, Dena G., van der Harst, Pim, Patel, Vickas V., Waterworth, Dawn M., Chu, Audrey Y., Oguro-Ando, Asami, Frayling, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502050/
https://www.ncbi.nlm.nih.gov/pubmed/36055212
http://dx.doi.org/10.1016/j.ajhg.2022.08.004

Ejemplares similares

Ejemplares similares